Healthcare & Biotechnologies
A Sector Essential to the Security and Development of Societies
Healthcare and biotechnologies constitute a fundamental pillar of economic, social, and strategic development. They encompass medical research, biotechnologies, medical devices, digital health, pharmaceutical production, and healthcare infrastructure.
In response to demographic, health, and technological challenges, the sector is evolving towards models that integrate scientific innovation, access to care, health system resilience, and health sovereignty.
Vision 2025–2030: Innovation, Prevention, and Resilience
Between 2025 and 2030, healthcare and biotechnologies will be structured around major dynamics:
-
acceleration of biomedical research and biotechnologies,
-
the rise of personalised and predictive medicine,
-
increasing integration of digital technologies and AI,
-
securing pharmaceutical production chains,
-
strengthening capacities for prevention and response to health crises.
The sector is becoming a strategic lever for resilience and national competitiveness.
France–India Analysis
France
France has a structured healthcare and biotech ecosystem, characterised by:
-
high-level medical and scientific research,
-
centres of excellence in biotechnologies, pharmaceuticals, and medical devices,
-
a demanding regulatory framework ensuring quality and safety,
-
strong coordination between public research, industry, and healthcare systems.
France positions itself as a key player in medical innovation, regulation, and quality of care.
India
India is a major global player in healthcare and biotechnologies, with:
-
large-scale pharmaceutical manufacturing capacity,
-
a central role in the production of medicines and vaccines,
-
a rapidly growing biotech ecosystem,
-
recognised expertise in clinical research and frugal innovation.
The country is a strategic partner for access to care, production, and large-scale deployment.
10 000 billion
in USD: estimated value of the global healthcare market by 2030
+ 8 %
average annual growth of the biotech sector
Top 5
European perspective: France’s position in biotechnologies and medical research.
Top 3
Global perspective: India’s position among pharmaceutical producers.
Shared Strategic Challenges
-
Health Sovereignty and Security of Supply
-
-
biomedical innovation and technology transfer,
-
equitable access to healthcare and treatments,
-
regulation, quality, and international compliance,
-
scientific and industrial cooperation.
-
-
Healthcare is becoming a global strategic issue, at the intersection of science, economics, and public policy.
-
-
A Structuring Axis of the France–India Corridor
-
-
France–India cooperation in healthcare and biotechnologies offers major opportunities in:
-
-
research and development of new therapies,
-
pharmaceutical production and distribution,
-
medical devices and digital health,
-
clinical trials and applied research,
-
training and development of medical skills.
-
-
FIBC Perspective and Positioning
-
-
The platform adopts a strategic and structured perspective on the France–India healthcare and biotech sector by:
-
-
facilitating dialogue between researchers, industrial players, institutions, and investors,
-
promoting scientific and industrial expertise,
-
supporting understanding of regulatory and health frameworks,
-
identifying responsible and sustainable cooperation opportunities.
-
-
This approach aims to position healthcare and biotechnologies as an essential pillar of France–India cooperation, serving innovation, health security, and long-term development.
Updates
